Logo image of KLDO

KALEIDO BIOSCIENCES INC (KLDO) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:KLDO - US4833471000 - Common Stock

0.29
-0.01 (-3.69%)
Last: 4/14/2022, 8:00:02 PM
0.3003
+0.01 (+3.55%)
After Hours: 4/14/2022, 8:00:02 PM
Fundamental Rating

1

Overall KLDO gets a fundamental rating of 1 out of 10. We evaluated KLDO against 192 industry peers in the Pharmaceuticals industry. KLDO may be in some trouble as it scores bad on both profitability and health. While showing a medium growth rate, KLDO is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

KLDO had negative earnings in the past year.
KLDO Yearly Net Income VS EBIT VS OCF VS FCFKLDO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 -20M -40M -60M -80M

1.2 Ratios

Industry RankSector Rank
ROA -180.08%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
KLDO Yearly ROA, ROE, ROICKLDO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 0 500 -500

1.3 Margins

The Operating Margin and Gross Margin are not available for KLDO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) -8155.92%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
KLDO Yearly Profit, Operating, Gross MarginsKLDO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 -2K -4K -6K -8K

More info and screens

1

2. Health

2.1 Basic Checks

KLDO has more shares outstanding than it did 1 year ago.
The debt/assets ratio for KLDO is higher compared to a year ago.
KLDO Yearly Shares OutstandingKLDO Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 10M 20M 30M 40M
KLDO Yearly Total Debt VS Total AssetsKLDO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 20M 40M 60M 80M

2.2 Solvency

KLDO has an Altman-Z score of -15.43. This is a bad value and indicates that KLDO is not financially healthy and even has some risk of bankruptcy.
A Debt/Equity ratio of 0.52 indicates that KLDO is somewhat dependend on debt financing.
Industry RankSector Rank
Debt/Equity 0.52
Debt/FCF N/A
Altman-Z -15.43
ROIC/WACCN/A
WACCN/A
KLDO Yearly LT Debt VS Equity VS FCFKLDO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 0 20M -20M 40M -40M -60M

2.3 Liquidity

KLDO has a Current Ratio of 1.43. This is a normal value and indicates that KLDO is financially healthy and should not expect problems in meeting its short term obligations.
A Quick Ratio of 1.43 indicates that KLDO should not have too much problems paying its short term obligations.
Industry RankSector Rank
Current Ratio 1.43
Quick Ratio 1.43
KLDO Yearly Current Assets VS Current LiabilitesKLDO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 20M 40M 60M

More info and screens

4

3. Growth

3.1 Past

KLDO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 11.65%, which is quite good.
KLDO shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 14.12%.
EPS 1Y (TTM)11.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%14.48%
Revenue 1Y (TTM)14.12%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%105%

3.2 Future

KLDO is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 0.99% yearly.
Based on estimates for the next years, KLDO will show a very strong growth in Revenue. The Revenue will grow by 252.50% on average per year.
EPS Next Y10.24%
EPS Next 2Y9.33%
EPS Next 3Y4.15%
EPS Next 5Y0.99%
Revenue Next Year-36.87%
Revenue Next 2Y401.97%
Revenue Next 3Y295.27%
Revenue Next 5Y252.5%

3.3 Evolution

KLDO Yearly Revenue VS EstimatesKLDO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M
KLDO Yearly EPS VS EstimatesKLDO Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 -1 -2 -3

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for KLDO. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for KLDO. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
KLDO Price Earnings VS Forward Price EarningsKLDO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA 0.05
KLDO Per share dataKLDO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1 -1.5 -2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y9.33%
EPS Next 3Y4.15%

More info and screens

0

5. Dividend

5.1 Amount

KLDO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

KALEIDO BIOSCIENCES INC

NASDAQ:KLDO (4/14/2022, 8:00:02 PM)

After market: 0.3003 +0.01 (+3.55%)

0.29

-0.01 (-3.69%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)03-01 2022-03-01/bmo
Earnings (Next)05-02 2022-05-02
Inst Owners0.01%
Inst Owner Change-97.43%
Ins Owners4.76%
Ins Owner Change0%
Market Cap12.36M
Revenue(TTM)1.11M
Net Income(TTM)-90.29M
Analysts76.67
Price Target11.91 (4006.9%)
Short Float %0.17%
Short Ratio0.01
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 11.17
P/FCF N/A
P/OCF N/A
P/B 1.17
P/tB N/A
EV/EBITDA 0.05
EPS(TTM)-2.16
EYN/A
EPS(NY)-2.07
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0.03
BVpS0.25
TBVpSN/A
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -180.08%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) -8155.92%
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3Y0%
ROICexgc growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.02
Health
Industry RankSector Rank
Debt/Equity 0.52
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.43
Quick Ratio 1.43
Altman-Z -15.43
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)11.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%14.48%
EPS Next Y10.24%
EPS Next 2Y9.33%
EPS Next 3Y4.15%
EPS Next 5Y0.99%
Revenue 1Y (TTM)14.12%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%105%
Revenue Next Year-36.87%
Revenue Next 2Y401.97%
Revenue Next 3Y295.27%
Revenue Next 5Y252.5%
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A

KALEIDO BIOSCIENCES INC / KLDO FAQ

Can you provide the ChartMill fundamental rating for KALEIDO BIOSCIENCES INC?

ChartMill assigns a fundamental rating of 2 / 10 to KLDO.


What is the valuation status for KLDO stock?

ChartMill assigns a valuation rating of 3 / 10 to KALEIDO BIOSCIENCES INC (KLDO). This can be considered as Overvalued.


Can you provide the profitability details for KALEIDO BIOSCIENCES INC?

KALEIDO BIOSCIENCES INC (KLDO) has a profitability rating of 1 / 10.


What is the financial health of KALEIDO BIOSCIENCES INC (KLDO) stock?

The financial health rating of KALEIDO BIOSCIENCES INC (KLDO) is 1 / 10.